{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001957","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.969980+00:00","generated_at":"2026-05-16T11:11:25.339667+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"SELLAS Life Sciences estimates $71.8M cash at Dec 31, 2025; $26.5M from warrant exercises post-quarter","bullets":["Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).","Received ~$26.5M in proceeds from common stock warrant exercises subsequent to year-end.","As of Jan 7, 2026, shares outstanding total 170,282,026.","No other operational or financial results disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001957","json":"https://secwatch.observer/filing/0001104659-26-001957.json","markdown":"https://secwatch.observer/filing/0001104659-26-001957.md","text":"https://secwatch.observer/filing/0001104659-26-001957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/0001104659-26-001957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/tm262494d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:11:25.339667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}